Will the Supreme Court Grant Cert in Myriad Patent Case?
By Mari Serebrov
Thursday, February 16, 2012
WASHINGTON The Supreme Court is set to consider Friday whether it wants the last word on the patentability of Myriad Genetics Inc.'s claims on the BRCA1 and BRCA2 genes, used in diagnostics for breast and ovarian cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.